Combined Radiation-Immunotherapy in locally advanced Bladder Cancer Prospective, single-arm, multicenter Phase-II Study to evaluate Safety and Efficacy of preoperative Radioimmunotherapy followed by radical Cystectomy in locally advanced Bladder Cancer (RACE-IT) - AB 65/18 of AUO

被引：0
|
作者：
Rexer, H. [1 ]
Schmid, S. [2 ]
Merseburger, A. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Tech Univ Munich, Klin Prufung LKP, Klinikum RDI, Urol Klin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany
[3] Deutsch Krebsgesell eV, Arbeitsgemeinschaft Urol Onkol, Kuno Fischer Str 8, D-14057 Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2020年 / 51卷 / 02期
关键词：
D O I：
10.1055/a-1017-4964
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 102
页数：2
相关论文
共 40 条
  • [31] STELLAR: A Phase II, Open-Label, Single-Arm, Prospective Clinical Study of Tislelizumab Combined with Sitravatinib as Consolidation Treatment after Chemoradiotherapy in Locally Advanced, Unresectable Non-Small-Cell Lung Cancer
    Ni, J.
    Chu, L.
    Chu, X.
    Yang, X.
    Yang, H.
    Deng, J.
    Fan, X.
    Zhao, W.
    Zhang, X.
    Lai, S.
    Gu, Y.
    Zhang, J.
    Liu, D.
    Mo, M.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E385 - E386
  • [32] Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
    Shang, Xiaobin
    Zhao, Gang
    Liang, Fei
    Zhang, Chen
    Zhang, Weihong
    Liu, Liang
    Li, Runmei
    Duan, Xiaofeng
    Ma, Zhao
    Yue, Jie
    Chen, Chuangui
    Meng, Bin
    Ren, Xiubao
    Jiang, Hongjing
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [33] Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).
    Lin, Zhenyu
    Zhang, Peng
    Zhao, Lei
    Ma, Hong
    Liu, Hongli
    Liu, Junli
    Xu, Ximing
    Lin, Dandan
    Zhang, Zhen
    Xia, Fan
    Tao, Kaixiong
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 192 - 192
  • [34] Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study
    Shinoda, Masahiro
    Shinkai, Masaharu
    Hara, Yu
    Tomaru, Kouji
    Manabe, Saki
    Murakami, Syuji
    Saito, Haruhiro
    Kobayashi, Nobuaki
    Miyazawa, Naoki
    Nishikawa, Masanori
    Kaneko, Takeshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (06) : 486 - 494
  • [35] Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00)
    Lehmann, Jan
    Kuehn, Michael
    Fischer, Claus
    Volkmer, Bjoern
    von Rundstedt, Friedrich
    Albers, Peter
    Becht, Eduard
    Bannowsky, Andreas
    Hofmann, Rainer
    Langbein, Sigrun
    Retz, Margitta
    Stoeckle, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial
    Jiang, Weizhong
    Chi, Pan
    Tao, Kaixiong
    Xu, Dongbo
    Yang, Chunkang
    Zheng, Rong
    Xu, Benhua
    Huang, Ying
    Chen, Zhifen
    Huang, Shenghui
    Xu, Zongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
    Peng, Zhi
    Liu, Tianshu
    Wei, Jia
    Wang, Airong
    He, Yifu
    Yang, Liuzhong
    Zhang, Xizhi
    Fan, Nanfeng
    Luo, Suxia
    Li, Zhen
    Gu, Kangsheng
    Lu, Jianwei
    Xu, Jianming
    Fan, Qingxia
    Xu, Ruihua
    Zhang, Liangming
    Li, Enxiao
    Sun, Yuping
    Yu, Guohua
    Bai, Chunmei
    Liu, Yong
    Zeng, Jiangzheng
    Ying, Jieer
    Liang, Xinjun
    Xu, Nong
    Gao, Chao
    Shu, Yongqian
    Ma, Dong
    Dai, Guanghai
    Li, Shengmian
    Deng, Ting
    Cui, Yuehong
    Fang, Jianmin
    Ba, Yi
    Shen, Lin
    CANCER COMMUNICATIONS, 2021, 41 (11) : 1173 - 1182
  • [38] Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20
    Rexer, Heidrun
    Kuebler, Hubert
    Retz, Margitta
    AKTUELLE UROLOGIE, 2021, 52 (03) : 220 - 221
  • [39] Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial
    Zhu, Xiaofei
    Ju, Xiaoping
    Cao, Fei
    Fang, Fang
    Qing, Shuiwang
    Shen, Yuxin
    Jia, Zhen
    Cao, Yangsen
    Zhang, Huojun
    BMJ OPEN, 2016, 6 (12):
  • [40] Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer: A single-arm phase II study
    Qu, F.
    Li, W.
    Yi, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S348 - S348
1234